Alliance for Pandemic Preparedness

May 25, 2021

Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Category:

Topic:

Keywords (Tags):

  • Prevalence of anti-SARS-CoV-2 antibodies in a cohort of 367 solid organ transplant recipients in France who received an mRNA COVID-19 vaccine was 1.4% at baseline, 6.3% prior to the second dose, and 34% at 1 month after the second dose. The vaccines were well tolerated with only one serious adverse event reported.

Marion et al. (May 25, 2021). Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine. https://doi.org/10.7326/M21-1341